For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Medipost Co., Ltd

USPTO Granted Patents = 15

% Expired Patents = 6.7

CIPO Patents = 2

EPO Patents = 10

Trademarks = 2

Forward Citations = 40

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Yoon-Sun Yang (13 out of 14 patents)

Won Il Oh (8 out of 8 patents)

Hong Bae Jeon (6 out of 8 patents)

4. Jong Wook Chang (5 out of 12 patents)

5. Wonil Oh (4 out of 5 patents)

6. Sun Jae Kwon (3 out of 3 patents)

7. Soo Jin Choi (3 out of 8 patents)

8. Mi Yeon Lee (3 out of 4 patents)

9. Miyeon Kim (2 out of 3 patents)

10. Ju-Yeon Kim (2 out of 2 patents)

11. Mee Hyun Jung (2 out of 2 patents)

12. Sang Young Jeong (2 out of 2 patents)

13. Hye Jin Jin (2 out of 2 patents)

14. Yun Sil Chang (1 out of 13 patents)

15. Yoon Sun Yang (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 12303534 - Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease (2025-05-20),

2. 11332715 - Method for culturing mesenchymal stem cells (2022-05-17),

3. 10307442 - Pharmaceutical composition for the prevention or treatment of a pulmonary disorder comprising mesenchymal stem cells having improved proliferation and differentiation capacity (2019-06-04),

4. 10294456 - Method for culturing mesenchymal stem cells (2019-05-21),

5. 10238692 - Composition comprising a culture solution of mesenchymal stem cells for the treatment of neural diseases (2019-03-26),

6. 10150950 - Method for culturing mesenchymal stem cells according to cell size (2018-12-11),

7. 9580687 - Method for culturing mesenchymal stem cells (2017-02-28),

8. 9498497 - Method of treating lung diseases using cells separated or proliferated from umbilical cord blood (2016-11-22),

9. 9439931 - Administering umbilical cord blood-derived mesenchymal stem cells to treat nerve injury (2016-09-13),

10. 9408892 - Treating cartilage defect with UCB-MSC expressing TSP-2 (2016-08-09),

11. 9387226 - Neural cell proliferation induced through the culture of neural cells with umbilical cord blood-derived mesenchymal stem cells (2016-07-12),

12. 9040298 - Method of selecting stem cells having high chondrogenic differentiation capability (2015-05-26),

13. 8614191 - Use of ICAM-1 for prevention or treatment of neurological diseases (2013-12-24),

14. 8506948 - UCB-MSCs comprising a tumor suppressor gene reduce the size of an IL-8 or GRO-αexpressing tumor (2013-08-13),

15. 7459307 - Composition for treatment of articular cartilage damage (2008-12-02),

Company Overview

Medipost Co., Ltd, based in Seoul, specializes in the development and manufacturing of advanced cell therapies and regenerative medicine products. The company focuses on innovative solutions for treating various diseases, leveraging its expertise in stem cell technology. Medipost is committed to enhancing patient outcomes through research and development in the biomedical field, aiming to address unmet medical needs both locally and globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

15 Patents

#282 in Seoul

#782 in South Korea

#39,959 in the World

Seoul, South Korea

Medipost Co., Ltd

Forward Citations = 40

27 inventors:

Yoon-Sun Yang (13 out of 14 patents)

Won Il Oh (8 out of 8 patents)

Hong Bae Jeon (6 out of 8 patents)

4. Jong Wook Chang (5 out of 12 patents)

5. Wonil Oh (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Medipost Co., Ltd. Retrieved from https://idiyas.com/company/medipost-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…